[Domestic first oral GLP-1 weight loss drug approved for marketing] On November 12, the official website of the State Food and Drug Administration showed that Eli Lilly’s Class 1 new drug Orfluglifloone Calcium Tablets (trade name: Muyuda) has been approved for marketing in China. This medicine is suitable for long-term weight management in adults whose initial body mass index (BMI) meets the following requirements on the basis of diet control and increased exercise: ≥30kg/m2 (obesity), or ≥27kg/m2 to <30kg/m2 (overweight) and accompanied by at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea syndrome, cardiovascular disease, etc.). It is the first oral GLP-1 weight loss drug approved in the country.